-
-
[1] Wu YL, Ahn MJ, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small cell lung cancer:Data from a randomized phase Ⅲ trial (AURA3)[J]. J Clin Oncol, 2018, 36(26):2702-2709. https://mdanderson.elsevierpure.com/en/publications/cns-efficacy-of-osimertinib-in-patients-with-t790m-positive-advan [2] Saboundji K, Auliac JB, Perol M, et al. Efficacy of osimertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastases pretreated with EGFR-tyrosine kinase inhibitors[J]. Target Oncol, 2018, 13(4):501-507. http://cn.bing.com/academic/profile?id=76e4f16b2482d69a7e2528738a08ad5d&encoded=0&v=paper_preview&mkt=zh-cn [3] Thein KZ, Swarup S, Ball S, et al. Incidence of cardiac toxicities in patients with advanced non-small cell lung cancer treated with osimertinib:A combined analysis of two phase Ⅲ randomized controlled trials[J]. Ann Oncol, 2018, 29(suppl 8):viii500. doi: 10.1056/NEJMoa1801005 [4] Qi WX, Fu S, Zhang Q, et al. Bevacizumab increases the risk of severe congestive heart failure in cancer patients:An up-to-date meta-analysis with a focus on different subgroups[J]. Clin Drug Investig, 2014, 34(10):681-690. http://cn.bing.com/academic/profile?id=c215e1e375534c0601144d208b31815e&encoded=0&v=paper_preview&mkt=zh-cn [5] Xing P, Mu Y, Wang Y, et al. Real world study of regimen containing bevacizumab as first-line therapy in chinese patients with advanced non-small cell lung cancer[J]. Thorac Cancer, 2018, 9(7):805-813. http://cn.bing.com/academic/profile?id=fb07d34953c14ae07bd418b44a0dcaa3&encoded=0&v=paper_preview&mkt=zh-cn [6] Tajiri K, Aonuma K, Sekine I. Cardiovascular toxic effects of targeted cancer therapy[J]. Jpn J Clin Oncol, 2017, 47(9):779-785. http://cn.bing.com/academic/profile?id=15bf71def90cbe0efeb55359bd151ab6&encoded=0&v=paper_preview&mkt=zh-cn [7] Miura S, Maemondo M, Iwashima A, et al. A phase Ⅱ study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016)[J]. Invest New Drugs, 2017, 35(2):227-234. [8] Zhao Y, Liu J, Cai X, et al. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer:Systematic review and network meta-analysis[J]. BMJ, 2019, 367:l5460. http://cn.bing.com/academic/profile?id=0a959d0764001d8a0c56fbd03422c46b&encoded=0&v=paper_preview&mkt=zh-cn -
点击查看大图
计量
- 文章访问数: 348
- HTML全文浏览量: 414
- PDF下载量: 8
- 被引次数: 0
下载:
